Treating prostate cancer with radiotherapy

Nature Reviews Clinical Oncology

Volumn 7, Issue 10, 2010, Pages 583-589

  Wilkins, Anna ^a   Parker, Chris ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DEFECATION DISORDER; EXTERNAL BEAM RADIOTHERAPY; FUNCTIONAL STATUS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LOWER URINARY TRACT SYMPTOM; MICTURITION DISORDER; OVERALL SURVIVAL; PATIENT DECISION MAKING; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION INDUCED NEOPLASM; RADIATION INJURY; RECTUM CANCER; REVIEW; RISK FACTOR; SECOND CANCER; SEXUAL DYSFUNCTION;

HUMANS; MALE; NEOPLASMS, RADIATION-INDUCED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RISK FACTORS;

EID: 77957569777     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.135     Document Type: Review

References (34)

1. Stephenson, A. J. et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J. Clin. Oncol. 27, 4300-4305 (2009).
2. Brandeis, J. M. et al. Quality of life outcomes after brachytherapy for early stage prostate cancer. J. Urol. 163, 851-857 (2000).
3. Arterbery, V. E. et al. Quality of life after permanent prostate implant. Semin. Surg. Oncol. 13, 461-464 (1997).
4. Sanda, M. G. et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358, 1250-1261 (2008).
5. Litwin, M. S., Lubeck, D. P., Henning, J. M. & Carroll, P. R. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J. Urol. 159, 1988-1992 (1998).
6. Christie, D. et al. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother. Oncol. 77, 117-125 (2005).
7. Lancar, R., Kramar, A. & Haie-Meder, C. Non-parametric methods for analysing recurrent complications of varying severity. Stat. Med. 14, 2701-2712 (1995).
8. Widmark, A. et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373, 301-308 (2009).
9. Fransson, P. et al. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol. 10, 370-380 (2009).
10. Osoba, D., Rodrigues, G., Myles, J., Zee, B. & Pater, J. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol. 16, 139-144 (1998).
11. Theobald, D. E. Cancer pain, fatigue, distress, and insomnia in cancer patients. Clin. Cornerstone 6 (Suppl. 1 D), S15-S21 (2004).
12. Pirl, W. F., Greer, J. A., Goode, M. & Smith, M. R. Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology 17, 148-153 (2008).
13. Dearnaley, D. P. et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiother. Oncol. 83, 31-41 (2007).
14. Kleinerman, R. A. et al. Second primary cancer after treatment for cervical cancer. An international cancer registries study. Cancer 76, 442-452 (1995).
15. Travis, L. B. et al. Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res. 56, 1564-1570 (1996).
16. Travis, L. B. et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J. Natl Cancer Inst. 89, 1429-1439 (1997).
17. Dores, G. M. et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J. Clin. Oncol. 20, 3484-3494 (2002).
18. Brenner, D. J., Curtis, R. E., Hall, E. J. & Ron, E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88, 398-406 (2000).
19. Neugut, A. I., Ahsan, H., Robinson, E. & Ennis, R. D. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer 79, 1600-1604 (1997).
20. Bhojani, N. et al. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17, 845 patients. Int. J. Radiat. Oncol. Biol. Phys. 76, 342-348 (2010).
21. Baxter, N. N., Tepper, J. E., Durham, S. B., Rothenberger, D. A. & Virnig, B. A. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology 128, 819-824 (2005).
22. Kendal, W. S., Eapen, L., Macrae, R., Malone, S. & Nicholas, G. Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 65, 661-668 (2006).
23. Andreyev, J. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol. 8, 1007-1017 (2007).
24. Fellin, G. et al. Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study. Radiother. Oncol. 93, 197-202 (2009).
25. van Tol-Geerdink, J. J. et al. Do patients with localized prostate cancer treatment really want more aggressive treatment? J. Clin. Oncol. 24, 4581-586 (2006).
26. Gore, J. L., Kwan, L., Lee, S. P., Reiter, R. E. & Litwin, M. S. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J. Natl Cancer Inst. 101, 888-892 (2009).
27. Vora, S. A., Wong, W. W., Schild, S. E., Ezzell, G. A. & Halyard, M. Y. Analysis of biochemical control and prognostic factors in patients treated with either low-dose threedimensional conformal radiation therapy or highdose intensity-modulated radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 68, 1053-1058 (2007).
28. Zelefsky, M. J. et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J. Urol. 166, 876-881 (2001).
29. Al-Mamgani, A., Heemsbergen, W. D., Peeters, S. T. & Lebesque, J. V. Role of intensitymodulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 73, 685-691 (2009).
30. rd. Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT. Int. J. Radiat. Oncol. Biol. Phys. 73, 53-60 (2009).
31. Hall, E. J. & Wuu, C. S. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int. J. Radiat. Oncol. Biol. Phys. 56, 83-88 (2003).
32. Hall, E. J. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int. J. Radiat. Oncol. Biol. Phys. 65, 1-7 (2006).
33. Ploquin, N. & Dunscombe, P. A cost-outcome analysis of Image-Guided Patient Repositioning in the radiation treatment of cancer of the prostate. Radiother. Oncol. 93, 25-31 (2009).
34. Konski, A. et al. Using decision analysis to determine the cost-effectiveness of intensitymodulated radiation therapy in the treatment of intermediate risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 66, 408-415 (2006).